Differential regulation of vascular endothelial growth factors by promoter-targeted shRNAs

Molecular Therapy Nucleic Acids

Volumn 4, Issue 5, 2015, Pages e243-

  Laham Karam, Nihay ^a   Lalli, Marianne ^a   Leinonen, Nastasia ^a   Ylä Herttuala, Seppo ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Lentiviral vector; Promoter targeted shRNA; RNA activation; RNA interference; RNAa; Vascular endothelial growth factors; Vasculogenesis

Indexed keywords

NUCLEAR RNA; SHORT HAIRPIN RNA; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC THERAPY; ARTICLE; CELL SPECIFICITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSDUCTION; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; UPREGULATION;

EID: 84959334785     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2015.16     Document Type: Article

References (41)

1. Mette, MF, Aufsatz, W, van der Winden, J, Matzke, MA and Matzke, AJ (2000). Transcriptional silencing and promoter methylation triggered by double-stranded RNA. EMBO J 19: 5194-5201.
2. Morris, KV, Chan, SW, Jacobsen, SE and Looney, DJ (2004). Small interfering RNA-induced transcriptional gene silencing in human cells. Science 305: 1289-1292.
3. Li, LC, Okino, ST, Zhao, H, Pookot, D, Place, RF, Urakami, S et al. (2006). Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci USA 103: 17337-17342.
4. Janowski, BA, Younger, ST, Hardy, DB, Ram, R, Huffman, KE and Corey, DR (2007). Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat Chem Biol 3: 166-173.
5. Place, RF, Noonan, EJ, Földes-Papp, Z and Li, LC (2010). Defining features and exploring chemical modifications to manipulate RNAa activity. Curr Pharm Biotechnol 11: 518-526.
6. Schwartz, JC, Younger, ST, Nguyen, NB, Hardy, DB, Monia, BP, Corey, DR et al. (2008). Antisense transcripts are targets for activating small RNAs. Nat Struct Mol Biol 15: 842-848.
7. Hawkins, PG, Santoso, S, Adams, C, Anest, V and Morris, KV (2009). Promoter targeted small RNAs induce long-term transcriptional gene silencing in human cells. Nucleic Acids Res 37: 2984-2995.
8. Huang, V, Qin, Y, Wang, J, Wang, X, Place, RF, Lin, G et al. (2010). RNAa is conserved in mammalian cells. PLoS One 5: e8848.
9. Suzuki, K and Kelleher, AD (2009). Transcriptional regulation by promoter targeted RNAs. Curr Top Med Chem 9: 1079-1087.
10. Turunen, MP, Lehtola, T, Heinonen, SE, Assefa, GS, Korpisalo, P, Girnary, R et al. (2009). Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanism: a novel example of epigenetherapy. Circ Res 105: 604-609.
11. Voutila, J, Sætrom, P, Mintz, P, Sun, G, Alluin, J, Rossi, JJ et al. (2012). Gene expression profile changes after short-activating RNA-mediated induction of endogenous pluripotency factors in human mesenchymal stem cells. Mol Ther Nucleic Acids 1: e35.
12. Turunen, MP, Husso, T, Musthafa, H, Laidinen, S, Dragneva, G, Laham-Karam, N et al. (2014). Epigenetic upregulation of endogenous VEGF-A reduces myocardial infarct size in mice. PLoS One 9: e89979.
13. Place, RF, Wang, J, Noonan, EJ, Meyers, R, Manoharan, M, Charisse, K et al. (2012). Formulation of small activating RNA into lipidoid nanoparticles inhibits xenograft prostate tumor growth by inducing p21 expression. Mol Ther Nucleic Acids 1: e15.
14. Kang, MR, Yang, G, Charisse, K, Epstein-Barash, H, Manoharan, M and Li, LC (2012). An orthotopic bladder tumor model and the evaluation of intravesical saRNA treatment. J Vis Exp 65: 4207.
15. Ren, S, Kang, MR, Wang, J, Huang, V, Place, RF, Sun, Y et al. (2013). Targeted induction of endogenous NKX3-1 by small activating RNA inhibits prostate tumor growth. Prostate 73: 1591-1601.
16. Watts, JK, Yu, D, Charisse, K, Montaillier, C, Potier, P, Manoharan, M et al. (2010). Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters. Nucleic Acids Res 38: 5242-5259.
17. Morris, KV, Santoso, S, Turner, AM, Pastori, C and Hawkins, PG (2008). Bidirectional transcription directs both transcriptional gene activation and suppression in human cells. PLoS Genet 4: e1000258.
18. Yang, K, Shen, J, Xie, YQ, Lin, YW, Qin, J, Mao, QQ et al. (2013). Promoter-targeted double-stranded small RNAs activate PAWR gene expression in human cancer cells. Int J Biochem Cell Biol 45: 1338-1346.
19. Mette, MF, Aufsatz, W, Kanno, T, Daxinger, L, Rovina, P, Matzke, M et al. (2005). Analysis of double-stranded RNA and small RNAs involved in RNA-mediated transcriptional gene silencing. Methods Mol Biol 309: 61-82.
20. Janowski, BA, Huffman, KE, Schwartz, JC, Ram, R, Nordsell, R, Shames, DS et al. (2006). Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. Nat Struct Mol Biol 13: 787-792.
21. Chu, Y, Yue, X, Younger, ST, Janowski, BA and Corey, DR (2010). Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter. Nucleic Acids Res 38: 7736-7748.
22. Matsui, M, Chu, Y, Zhang, H, Gagnon, KT, Shaikh, S, Kuchimanchi, S et al. (2013). Promoter RNA links transcriptional regulation of inflammatory pathway genes. Nucleic Acids Res 41: 10086-10109.
23. Place, RF, Li, LC, Pookot, D, Noonan, EJ and Dahiya, R (2008). MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci USA 105: 1608-1613.
24. Matsui, M, Sakurai, F, Elbashir, S, Foster, DJ, Manoharan, M and Corey, DR (2010). Activation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter. Chem Biol 17: 1344-1355.
25. Hu, J, Chen, Z, Xia, D, Wu, J, Xu, H and Ye, ZQ (2012). Promoter-associated small double-stranded RNA interacts with heterogeneous nuclear ribonucleoprotein A2/B1 to induce transcriptional activation. Biochem J 447: 407-416.
26. Ylä-Herttuala, S, Rissanen, TT, Vajanto, I and Hartikainen, J (2007). Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 49: 1015-1026.
27. Lohela, M, Bry, M, Tammela, T and Alitalo, K (2009). VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21: 154-165.
28. Koch, S, Tugues, S, Li, X, Gualandi, L and Claesson-Welsh, L (2011). Signal transduction by vascular endothelial growth factor receptors. Biochem J 437: 169-183.
29. Ylä-Herttuala, S (2013). Cardiovascular gene therapy with vascular endothelial growth factors. Gene 525: 217-219.
30. Samaranayake, H, Määttä, AM, Pikkarainen, J and Ylä-Herttuala, S (2010). Future prospects and challenges of antiangiogenic cancer gene therapy. Hum Gene Ther 21: 381-396.
31. Vuorio, T, Jauhiainen, S and Ylä-Herttuala, S (2012). Pro- and anti-angiogenic therapy and atherosclerosis with special emphasis on vascular endothelial growth factors. Expert Opin Biol Ther 12: 79-92.
32. Ahlenstiel, CL, Lim, HG, Cooper, DA, Ishida, T, Kelleher, AD and Suzuki, K (2012). Direct evidence of nuclear Argonaute distribution during transcriptional silencing links the actin cytoskeleton to nuclear RNAi machinery in human cells. Nucleic Acids Res 40: 1579-1595.
33. Gagnon, KT, Li, L, Chu, Y, Janowski, BA and Corey, DR (2014). RNAi factors are present and active in human cell nuclei. Cell Rep 6: 211-221.
34. Matsui, M, Prakash, TP and Corey, DR (2013). Transcriptional silencing by single-stranded RNAs targeting a noncoding RNA that overlaps a gene promoter. ACS Chem Biol 8: 122-126.
35. Burroughs, AM, Ando, Y, de Hoon, MJ, Tomaru, Y, Suzuki, H, Hayashizaki, Y et al. (2011). Deep-sequencing of human Argonaute-associated small RNAs provides insight into miRNA sorting and reveals Argonaute association with RNA fragments of diverse origin. RNA Biol 8: 158-177.
36. Zamudio, JR, Kelly, TJ and Sharp, PA (2014). Argonaute-bound small RNAs from promoter-proximal RNA polymerase II. Cell 156: 920-934.
37. de Laat, W and Duboule, D (2013). Topology of mammalian developmental enhancers and their regulatory landscapes. Nature 502: 499-506.
38. Ghavi-Helm, Y, Klein, FA, Pakozdi, T, Ciglar, L, Noordermeer, D, Huber, W et al. (2014). Enhancer loops appear stable during development and are associated with paused polymerase. Nature 512: 96-100.
39. Mäkinen, PI, Koponen, JK, Kärkkäinen, AM, Malm, TM, Pulkkinen, KH, Koistinaho, J et al. (2006). Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain. J Gene Med 8: 433-441.
40. Melamed, D, Mark-Danieli, M, Kenan-Eichler, M, Kraus, O, Castiel, A, Laham, N et al. (2004). The conserved carboxy terminus of the capsid domain of human immunodeficiency virus type 1 gag protein is important for virion assembly and release. J Virol 78: 9675-9688.
41. Carey, MF, Peterson, CL and Smale, S T. Chromatin Immunoprecipitation (ChIP). CSHL Press: Cold Spring Harbor, NY, 2009.